Clinical Trial Update: Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, immunogenicity, and efficacy of the GSK3878858A Staphylococcus aureus vaccine in healthy adults and in adults 18-64 with a recen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin and Soft Tissue Infection
• Soft Tissue Infection
• Staphylococcus Aureus Infection

Drugs mentioned

• GSK3878858A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Soft Tissue | Phase 2 | Status: COMPLETED | Results posted: 2025-05-08